Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Acquisitions & Divestments (2023 - 2026)

Summit Therapeutics filings provide 4 years of Change in Acquisitions & Divestments readings, the most recent being $177.3 million for Q1 2026.

  • Quarterly Change in Acquisitions & Divestments rose 10.44% to $177.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $328.1 million through Mar 2026, down 38.96% year-over-year, with the annual reading at $311.3 million for FY2025, 36.44% down from the prior year.
  • Change in Acquisitions & Divestments hit $177.3 million in Q1 2026 for Summit Therapeutics, up from $150.8 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $233.0 million in Q4 2024 and bottomed at $38.2 million in Q2 2023.
  • Average Change in Acquisitions & Divestments over 4 years is $118.7 million, with a median of $111.1 million recorded in 2023.
  • Peak annual rise in Change in Acquisitions & Divestments hit 284.66% in 2024, while the deepest fall reached 32.37% in 2024.
  • Summit Therapeutics' Change in Acquisitions & Divestments stood at $60.6 million in 2023, then soared by 284.66% to $233.0 million in 2024, then crashed by 35.27% to $150.8 million in 2025, then increased by 17.56% to $177.3 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Change in Acquisitions & Divestments are $177.3 million (Q1 2026), $150.8 million (Q2 2025), and $160.5 million (Q1 2025).